Cadence Pharmaceuticals Inc

Cadence Pharmaceuticals — Investor Presentation (September 2011)

22 slides from Cadence Pharmaceuticals's investor presentation, Sep 28, 2011

  1. Slide 1: Corporate Overview

    Corporate Overview Improving the lives of hospitalized patients September 2011 Exhibit 99.1

  2. Slide 2: Caution on forward-looking statements

    Caution on forward-looking statements © 2011 Cadence Pharmaceuticals, Inc. All rights reserved. This presentation includes forward-looking statements, which are based on our current beliefs and expectations. Such statements include, without limitation, statements regarding: the anticipated U.S. mark

  3. Slide 3: Cadence: investment highlights

    Cadence: investment highlights Hospital-focused specialty pharmaceutical company OFIRMEV ® launched with broad pain and fever indication in January 2011 – Rapid formulary adoption demonstrated – Established hospital sales team provides a core platform for the acquisition of additional products – Man

  4. Slide 4: Product overview

    OFIRMEV ® : product overview OFIRMEV (acetaminophen) injection – Proprietary IV acetaminophen formulation – First and only IV formulation of acetaminophen approved in the United States – New class of IV medication • non-narcotic / opioid • non-NSAID – Same formulation of IV acetaminophen marketed by

  5. Slide 5: Broad indication supports message

    OFIRMEV ® : • Significant pain relief • Reduced opioid consumption* • Improved patient satisfaction • Established safety profile Message Broad Indication • Mild to moderate pain • Moderate to severe pain with adjunctive opioids • Reduction of fever • Adults and children 2 and older indication suppor

  6. Slide 6: Strong foundation for commercial success

    OFIRMEV ® : Effective Pain Control Experienced Hospital Sales Force Economic Value strong foundation for commercial success • Sales force average >10 years hospital selling experience • Extensive relationships, significant overlap with prior territory • Substantial hospital commercial experience thr

  7. Slide 7: Strong early launch indicators

    OFIRMEV ® : strong early launch indicators* Rapid formulary adoption – On formulary in over 1,150 hospitals – Mix of formulary wins is representative of overall target market – Includes major academic medical centers and large community healthcare systems Most hospitals approved OFIRMEV without rest

  8. Slide 8: Multi-step launch process

    Hospital products: Regulatory Approval Physician Access Formulary Access Sales multi-step launch process

  9. Slide 9: Adoption process

    Phase III Increase Doses Per Patient Phase II Broaden Physician Utilization Phase I Create Access OFIRMEV ® : adoption process

  10. Slide 10: Cadence Pharmaceuticals

    cadence PHARMACEUTICALS

  11. Slide 11: Strong revenue ramp

    OFIRMEV ® : strong revenue ramp Source: Wolters Kluwer Pharma Solutions, Source® PHAST Institution. Cubist Pharmaceuticals, Inc. Form 10-Q reports. Based on Cadence comparison to other selected product launches in hospital market over period March – Aug 2011. OPAT utilization from Cubist Corporate P

  12. Slide 12: Limitations of other IV pain therapies

    Limitations of other IV pain therapies Opioids NSAIDs Sedation Nausea Vomiting Constipation Headache Cognitive impairment Respiratory depression Black Box Warning Bleeding GI complications Kidney complications Cardiovascular risks Prolonged recovery Increased length of stay Higher costs to the insti

  13. Slide 13: Multi-modal analgesia: the norms

    Pain Intensity Current US Approach Current EU Approach Multi-modal analgesia: Severe Opioids IV acetaminophen + opioids Moderate Opioids IV acetaminophen +/- opioids* Mild Opioids IV acetaminophen the norms * First post operative analgesic drug, then add opioids if necessary

  14. Slide 14: Pivotal acute pain clinical trial

    IV acetaminophen placebo p-value Sinatra Study: IV acetaminophen placebo p-value Sinatra, et al. Anesthesiology, V 102, No. 4, April 2005. Weighted sums of pain relief over 6hrs 6.6 2.2 <0.05 Patient Satisfaction (Good/excellent – hrs) 41% 23% <0.01 Morphine consumption over 24 hrs** 38.3 mg (33% )

  15. Slide 15: Consistent opioid reduction across studies

    Pain Intensity Opioid Reduction* Time p Value Consistent opioid reduction across studies Severe 33% 24h <0.01 61% 24h <0.05 Moderate 53% 0-6h 0.016 Mild 86% 24h <0.001 78% 24h <0.01 *Reduction in number of patients requiring analgesic rescue with ketorolac and fentanyl 1) Sinatra, et al, 2005; 2) Me

  16. Slide 16: Economic value

    OFIRMEV ® : economic value Placebo-controlled studies using IV acetaminophen demonstrated results that may be associated with possible hospital cost savings: – Decreased opioid consumption * • Total hip/knee replacement (1) • Total hip replacement (2, 3) • Adult tonsillectomy (4) • Endoscopic thyroi

  17. Slide 17: IV acetaminophen: EU market leader

    IV acetaminophen: Source: IMS Data *(SOM – Share of market) • >20% unit share of injectable analgesic market EU market leader

  18. Slide 18: The UK experience: an appropriate model

    The UK experience: an appropriate model UK treatment paradigms for moderate and acute pain are similar to those in the US – Higher opioid than NSAID usage – Multimodal pain therapy Perfalgan, BMY’s IV acetaminophen – Launched in 2004 – Has taken approximately 35% market share – Most share taken from

  19. Slide 19: Oral opioids: acetaminophen combinations dominate

    Oral opioids: acetaminophen combinations dominate Opioid-acetaminophen combinations Opioid-only products Opioid-NSAID combinations 73% 25% 1% Source: IMS data, 2008. 73% of oral opioid doses sold in U.S. contain acetaminophen Approximately 14.4 billion total doses sold in 2008 Acetaminophen + hydroc

  20. Slide 20: US market opportunity

    OFIRMEV ® : US market opportunity US and EU injectable analgesics markets are similarly sized Approximately 87 million IV acetaminophen units sold in Europe in 2009 Continued EU market expansion after introduction of IV acetaminophen Sources: IMS data, company estimates

  21. Slide 21: Cadence: financial position

    Cadence: financial position 12 Months Ended 12/31/10 (MM) 6 Months Ended 6/30/11 (MM) Operating expenses $ 54.9 $ 46.4 Cash, cash equivalents & short-term investments $134.1 $ 94.1 Shares outstanding 63.1 63.6

  22. Slide 22: Product overview

    OFIRMEV ® : product overview OFIRMEV (acetaminophen) injection – Proprietary IV acetaminophen formulation – First and only IV formulation of acetaminophen approved in the United States – New Class of IV Analgesic OFIRMEV launched with broad pain and fever indication in January 2011 – Rapid formulary

Cadence Pharmaceuticals — Investor Presentation (September 2011) on 6ix